PAVMPAVMHealthcare · Medical Devices

PAVM Stock Forecast: PAVmed, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.14
−5.42% on the day

The median 12-month analyst price target for PAVmed, Inc. is $57. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 31 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$9.6M
Ticker Nerd rank
31/ 100
Median analyst target
$57
Analysts covering
2
Revenue$33K+450.0% y/y
Operating income−$6.7M
Net income−$6.6M
Free cash flow−$2.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−30.4%
1M
−49.1%
YTD
−82.9%
1Y
−89.4%
From 52W high
−90.6%
From 52W low
0.0%
$1
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores PAVmed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
31/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
97
Revisions
68
Growth
53
Quality
28
Volatility
17
Momentum
6
Value
5
Issuance
3

Accruals (97): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (3): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PAVM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PAVM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26PAVMHigh $57Median $57Low $57

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$57
Low
$57
Median
$57
High
Recent analyst actionsNewest first

Of the 17 most recent actions, 1 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
27 Aug 2026Ascendiant CapitalMaintainsBuy$56 → $57
8 June 2026Ascendiant CapitalMaintainsBuy$65 → $56
9 Apr 2026Ascendiant CapitalMaintainsBuy—
10 Dec 2025Ascendiant CapitalMaintainsBuy—
6 Oct 2025Ascendiant CapitalMaintainsBuy—
6 June 2025Ascendiant CapitalMaintainsBuy—
21 Apr 2025Ascendiant CapitalMaintainsBuy—
9 Dec 2024Ascendiant CapitalMaintainsBuy—
10 Sept 2024Ascendiant CapitalMaintainsBuy$22 → $21
18 Aug 2023Cantor FitzgeraldReiteratesNeutral$1.40
20 Jan 2023Cantor FitzgeraldDowngradeNeutral$4.00 → $1.50
18 Jan 2023Lake StreetMaintainsBuy$5.00 → $1.50
17 Aug 2022Lake StreetMaintainsBuy$7.00 → $5.00
30 Mar 2021Cantor FitzgeraldInitiatesOverweight—
5 Nov 2020Ascendiant CapitalInitiatesBuy—
13 Oct 2020Lake StreetInitiatesBuy—
28 June 2018Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PAVM.

Market Radar

This page is one stock. Monday covers all of them.

PAVM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PAVM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, PAVmed, Inc. returned −89.4% against +6.9% for the S&P 500, dividends included.

PAVM vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26PAVMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PAVM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
64.6×

Cheaper than 4% of US stocks

Price / book
0.4×

Cheaper than 90% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−130.6%

Higher than 11% of US stocks

Return on assets
−48.8%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • PAVmed, Inc. has a market value of $9.6M and an enterprise value of $8.6M.

  • Revenue in the twelve months to 30 June 2026: $112K. The latest quarter grew 450.0% year on year.

  • Net income over the same four quarters: −$16.4M, a −14669.6% net margin.

  • Diluted earnings per share, trailing twelve months: −$75.49.

  • Free cash flow in the twelve months to 30 June 2026: −$7.8M.

  • Shares outstanding: 7.3M.

  • PAVmed, Inc. employs 41 people — $3K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

PAVM and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
PAVMPAVmed, Inc.$9.6M31
AEMDAethlon Medical, Inc.$8.8M24
SINTSINTX Technologies, Inc.$8.3M41
HSCSHeartSciences, Inc.$10.3M43
LFWDLifeward Ltd.$7.9M15
IRIXIRIDEX Corp.$7.6M47
ITOCiTonic Holdings Ltd.$11.6M15

Take a look at PAVM’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own PAVmed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about PAVM

What is the PAVM stock price forecast for 2026-2027?

The median 12-month analyst price target for PAVmed, Inc. is $57. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PAVM stock a buy right now?

Of the 2 analysts covering PAVmed, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PAVmed, Inc. 31 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PAVM?

As at 21 Nov 2026, PAVmed, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (97 of 100).

Will PAVM stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $57, and Ticker Nerd's factor model ranks PAVmed, Inc. 31 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PAVM stock forecast for 2030?

No analyst covering PAVmed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PAVM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $57 to $57 over the next 12 months.

How has PAVM stock performed over the past year?

PAVmed, Inc. returned -89.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does PAVmed, Inc. do?

Pavmed Inc. is a diversified commercial-stage medical technology company focused on developing, acquiring, and commercializing products across medical devices, diagnostics, and digital health. The company’s portfolio addresses unmet clinical needs in areas such as gastrointestinal endoscopy, cancer detection, remote patient monitoring, vascular access, and other minimally invasive care settings.

Company

About PAVmed, Inc.

Pavmed Inc. is a diversified commercial-stage medical technology company focused on developing, acquiring, and commercializing products across medical devices, diagnostics, and digital health. The company’s portfolio addresses unmet clinical needs in areas such as gastrointestinal endoscopy, cancer detection, remote patient monitoring, vascular access, and other minimally invasive care settings. Through its operating subsidiaries, Pavmed supports products and platforms designed for use by healthcare providers, hospitals, and patients, with an emphasis on improving workflow, diagnosis, and care delivery. Its current business is centered on bringing novel healthcare technologies into commercial use and expanding access to tools that support prevention, treatment, and ongoing patient management.

CEO Dr. Lishan Aklog M.D. · 41 employees · United States · https://www.pavmed.com